Testing the Right Target and Right Drug at the Right Stage

被引：415

作者：

Sperling, Reisa A. ^{[1
]}

Jack, Clifford R., Jr. ^{[2
]}

Aisen, Paul S. ^{[3
]}

机构：

[1] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Ctr Alzheimer Res & Treatment,Brigham & Womens Ho, Boston, MA 02446 USA

[2] Mayo Clin, Dept Radiol, Rochester, MN 55902 USA

[3] Univ Calif San Diego, Dept Neurosci, La Jolla, CA 92093 USA

来源：

SCIENCE TRANSLATIONAL MEDICINE | 2011年 / 3卷 / 111期

关键词：

MILD COGNITIVE IMPAIRMENT; ALZHEIMERS-DISEASE; AMYLOID DEPOSITION; A-BETA; CSF BIOMARKERS; ASSOCIATION; MRI; RECOMMENDATIONS; PROGRESSION; PREDICTION;

D O I：

10.1126/scitranslmed.3002609

中图分类号：

Q2 [细胞生物学];

学科分类号：

071009 ; 090102 ;

摘要：

Alzheimer's disease (AD) is the only leading cause of death for which no disease-modifying therapy is currently available. Recent disappointing trial results at the dementia stage of AD have raised multiple questions about our current approaches to the development of disease-modifying agents. Converging evidence suggests that the pathophysiological process of AD begins many years before the onset of dementia. So why do we keep testing drugs aimed at the initial stages of the disease process in patients at the end-stage of the illness?

引用

页数：5

共 36 条

[21] Aβ immunotherapy leads to clearance of early, but not late, hyperphosphorylated tau aggregates via the proteasome
Oddo, S
Billings, L
Kesslak, JP
Cribbs, DH
LaFerla, FM
[J]. NEURON, 2004, 43 (03) : 321 - 332
[22] Mechanism of Amyloid Removal in Patients With Alzheimer Disease Treated With Gantenerumab
Ostrowitzki, Susanne
Deptula, Dennis
Thurfjell, Lennart
Barkhof, Frederik
Bohrmann, Bernd
Brooks, David J.
Klunk, William E.
Ashford, Elizabeth
Yoo, Kisook
Xu, Zhi-Xin
Loetscher, Hansruedi
Santarelli, Luca
[J]. ARCHIVES OF NEUROLOGY, 2012, 69 (02) : 198 - 207
[23] Cognition, Reserve, and Amyloid Deposition in Normal Aging
Rentz, Dorene M.
Locascio, Joseph J.
Becker, John A.
Moran, Erin K.
Eng, Elisha
Buckner, Randy L.
Sperling, Reisa A.
Johnson, Keith A.
[J]. ANNALS OF NEUROLOGY, 2010, 67 (03) : 353 - 364
[24] Biochemical markers in persons with preclinical familial Alzheimer disease
Ringman, J. M.
Younkin, S. G.
Pratico, D.
Seltzer, W.
Cole, G. M.
Geschwind, D. H.
Rodriguez-Agudelo, Y.
Schaffer, B.
Fein, J.
Sokolow, S.
Rosario, E. R.
Gylys, K. H.
Varpetian, A.
Medina, L. D.
Cummings, J. L.
[J]. NEUROLOGY, 2008, 71 (02) : 85 - 92
[25] 11C-PiB PET assessment of change in fibrillar amyloid-β load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study
Rinne, Juha O.
Brooks, David J.
Rossor, Martin N.
Fox, Nick C.
Bullock, Roger
Klunk, William E.
Mathis, Chester A.
Blennow, Kaj
Barakos, Jerome
Okello, Aren A.
de Llano, Sofia Rodriguez Martinez
Liu, Enchi
Koller, Martin
Gregg, Keith M.
Schenk, Dale
Black, Ronald
Grundman, Michael
[J]. LANCET NEUROLOGY, 2010, 9 (04) : 363 - 372
[26] Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging
Rowe, Christopher C.
Ellis, Kathryn A.
Rimajova, Miroslava
Bourgeat, Pierrick
Pike, Kerryn E.
Jones, Gareth
Fripp, Jurgen
Tochon-Danguy, Henri
Morandeau, Laurence
O'Keefe, Graeme
Price, Roger
Raniga, Parnesh
Robins, Peter
Acosta, Oscar
Lenzo, Nat
Szoeke, Cassandra
Salvado, Olivier
Head, Richard
Martins, Ralph
Masters, Colin L.
Ames, David
Villemagne, Victor L.
[J]. NEUROBIOLOGY OF AGING, 2010, 31 (08) : 1275 - 1283
[27] Increased Brain Atrophy Rates in Cognitively Normal Older Adults with Low Cerebrospinal Fluid Aβ1-42
Schott, Jonathan M.
Bartlett, Jonathan W.
Fox, Nick C.
Barnes, Josephine
[J]. ANNALS OF NEUROLOGY, 2010, 68 (06) : 825 - 834
[28] Resolving controversies on the path to Alzheimer's therapeutics
Selkoe, Dennis J.
[J]. NATURE MEDICINE, 2011, 17 (09) : 1060 - 1065
[29] Cerebrospinal fluid beta-amyloid 42 is reduced before the onset of sporadic dementia: A population-based study in 85-year-olds
Skoog, I
Davidsson, P
Aevarsson, O
Vanderstichele, H
Vanmechelen, E
Blennow, K
[J]. DEMENTIA AND GERIATRIC COGNITIVE DISORDERS, 2003, 15 (03) : 169 - 176
[30] Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: Recommendations from the Alzheimer's Association Research Roundtable Workgroup
Sperling, Reisa A.
Jack, Clifford R., Jr.
Black, Sandra E.
Frosch, Matthew P.
Greenberg, Steven M.
Hyman, Bradley T.
Scheitens, Philip
Carrillo, Maria C.
Thies, William
Bednar, Martin M.
Black, Ronald S.
Brashear, H. Robert
Grundman, Michael
Siemers, Eric R.
Feldman, Howard H.
Schindler, Rachel J.
[J]. ALZHEIMERS & DEMENTIA, 2011, 7 (04) : 367 - 385

← 1 2 3 4 →